Physician profile
Michael J Slade
NPI 1144740200
$10,176.33
in general payments reported to CMS, 2019-2025
16 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.95 · 2021: $99.99 · 2022: $76.95 · 2024: $8,473 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,875 · Consulting Fee: $1,281 · Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,875.25 |
| Consulting Fee | $1,281.00 |
| Food and Beverage | $743.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $8,154.71 | 2024 | |
| Legend Biotech USA INC. | $1,314.53 | 2024-2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $160.63 | 2024-2025 | Sotyktu, Cobenfy |
| Genzyme Corporation | $139.22 | 2024 | |
| Kite Pharma, INC. | $130.35 | 2024 | Yescarta |
| Incyte Corporation | $99.99 | 2021 | |
| Astellas Pharma US INC | $99.95 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.95 | 2022 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.